Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dr. Taylor receives 200,000 stock options with a 10-year term and vesting over four years
- Dr. Taylor also receives 100,000 restricted stock units that vest over three years
- Agenus grants 250,000 stock options to Dr. Taylor that vest in four equal annual installments
- None.
The awards to Dr. Taylor consist of (i) nonqualified options to purchase 200,000 shares of Agenus common stock with a 10-year term, an exercise price equal to the closing price of Agenus' common stock on the Grant Date, and vesting over four years in equal annual installments, (ii) 100,000 restricted stock units that vest over three years in equal annual installments and (iii) 250,000 nonqualified options that vest in four equal annual installments starting on the second anniversary of Dr. Taylor joining Agenus; provided that each equity award to Dr. Taylor is subject to him maintaining a service relationship with the company through the relevant vest date.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20230901306999/en/
Investors
917-362-1370
investor@agenusbio.com
Media
781-674-4784
communications@agenusbio.com
Source: Agenus Inc.
